Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis Supplementary table 1

Aim: This meta-analysis aimed to investigate the clinical value of calprotectin in rheumatoid arthritis (RA) patients. Methods: The data regarding blood calprotectin levels in RA patients were retrieved from PubMed, Embase, Web of Science and Cochrane databases. Results: Thirty-one eligible articles were included. Calprotectin was increased in RA patients compared with healthy controls (mean difference [MD] = 1.48, 95% CI: 1.16–1.79). Calprotectin was positively associated with C-reactive protein (correlation coefficient [CC] = 0.58, 95% CI: 0.53–0.63) and disease activity score (CC = 0.48, 95% CI: 0.38–0.58) in RA patients. Interestingly, calprotectin showed an increased trend in RA responders compared with nonresponders, but without statistical significance (MD = 0.38, 95% CI: -0.09–0.85). Conclusion: Blood calprotectin relates to disease risk, inflammation and activity in RA patients.

研究目的：本荟萃分析旨在探讨钙卫蛋白（calprotectin）在类风湿关节炎（rheumatoid arthritis, RA）患者中的临床价值。
方法：从PubMed、Embase、Web of Science及Cochrane数据库中检索类风湿关节炎患者血液钙卫蛋白水平的相关研究数据。
结果：最终纳入31篇符合纳入标准的文献。与健康对照人群相比，类风湿关节炎患者的钙卫蛋白水平显著升高（均数差[MD]=1.48，95%置信区间[CI]：1.16~1.79）。类风湿关节炎患者的钙卫蛋白水平与C反应蛋白（相关系数[CC]=0.58，95%CI：0.53~0.63）及疾病活动度评分（相关系数[CC]=0.48，95%CI：0.38~0.58）呈正相关。值得注意的是，与无应答者相比，类风湿关节炎应答者的钙卫蛋白水平呈升高趋势，但差异无统计学意义（MD=0.38，95%CI：-0.09~0.85）。
结论：血液钙卫蛋白与类风湿关节炎患者的疾病风险、炎症状态及疾病活动度密切相关。